Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rufinamide
Drug ID BADD_D01977
Description Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Indications and Usage Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome.
Marketing Status approved
ATC Code N03AF03
DrugBank ID DB06201
KEGG ID D05775
MeSH ID C079703
PubChem ID 129228
TTD Drug ID D0MD2L
NDC Product Code 66039-881; 42571-392; 59651-616; 59651-617; 68462-714; 71428-009; 31722-599; 62856-582; 62856-584; 68180-802; 62856-583; 68180-804; 14501-0058; 50923-0614; 42571-391; 0378-2331; 68180-797; 68462-713; 0054-0528; 51148-010; 65977-0068; 69452-223; 0054-0426; 46438-0661; 46438-0662; 69766-050; 31722-598; 0378-2330; 51148-009; 66005-0037; 59651-563; 68180-803; 0054-0425; 67877-673; 51148-008
UNII WFW942PR79
Synonyms rufinamide | 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide | CGP 33101 | CGP-33101 | Inovelon
Chemical Information
Molecular Formula C10H8F2N4O
CAS Registry Number 106308-44-5
SMILES C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Seizure17.12.03.001--
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Status epilepticus17.12.03.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tremor17.01.06.002--
Urethral disorder20.07.01.002--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary tract disorder20.08.01.001--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Contusion24.07.06.001; 23.03.11.002; 12.01.06.001; 15.03.05.007--
Lymphatic disorder01.09.01.003--Not Available
Urine output increased13.13.03.002--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Hepatobiliary disease09.01.08.003--Not Available
The 3th Page    First    Pre   3    Total 3 Pages